• Kythera Biopharmaceuticals Inc., of Calabasas, Calif., disclosed positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress in Monte Carlo, Monaco.